Earnings summaries and quarterly performance for Structure Therapeutics.
Executive leadership at Structure Therapeutics.
Board of directors at Structure Therapeutics.
Research analysts covering Structure Therapeutics.
Recent press releases and 8-K filings for GPCR.
Structure Therapeutics Discusses Pipeline and Strategy at Cantor Global Healthcare Conference
GPCR
New Projects/Investments
- Structure Therapeutics is focused on developing oral small molecules for obesity and diabetes, anticipating that these will expand the market, particularly through primary care physicians.
- The company expects two data readouts for its lead oral GLP-1 molecule, aleniglapron, from the Access and Access 2 studies by the end of 2025.
- Structure Therapeutics also plans to advance its oral amylin small molecule (2671) into the clinic by the end of 2025, with potential for both monotherapy and combination use.
- The company announced three new studies for aleniglapron, including a switch study, a body composition study, and a study for individuals with type 2 diabetes and obesity, to inform its Phase 3 design and broaden its label.
- Structure Therapeutics is actively seeking a strategic partner for commercialization to help realize the full potential of aleniglapron across various indications beyond chronic weight management.
Sep 3, 2025, 8:56 PM
Quarterly earnings call transcripts for Structure Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Structure Therapeutics's earnings for you
Get instant analysis when filings drop